Imunon, Inc. quarterly report, Q2 FY2021

Business context and reporting period

This is Celsion Corporation’s unaudited Form 10-Q for the quarter and six months ended June 30, 2021 (ticker CLSN). The filing describes a clinical-stage biotechnology business; it identifies GEN-1, an ovarian-cancer immunotherapy, and ThermoDox, a heat-activated chemotherapy, as pipeline candidates, alongside early-stage vaccine and nucleic-acid delivery platforms. Revenue remained limited to licensing revenue.

Financial results and liquidity

• At June 30, cash and cash equivalents were $26.44 million; available-for-sale short-term investments were $31.92 million; accrued investment interest was $0.11 million; and restricted cash was $6.00 million. Together these totaled approximately $64.5 million, as cited by management.
• Current assets were $60.31 million and current liabilities $5.38 million, yielding working capital of $54.93 million, compared with $12.07 million at December 31, 2020.
• Total liabilities were $18.96 million. Notes payable, net of financing costs, totaled $5.76 million, all classified as non-current. The June 2021 SVB facility provided $10 million, of which $6 million was drawn to repay Horizon; the remaining $4 million was available to draw within 12 months. The SVB loan bears a variable Prime-based rate, initially 3.25%, and has a 3% end-of-term fee. A $6 million cash reserve is restricted as collateral.
• Cash flow from investing activities was a $32.15 million outflow, largely reflecting investment-security purchases; financing activities provided $54.78 million, primarily from equity issuance and the SVB facility.
• Operating margins and profitability are not meaningful measures for this pre-commercial company; the filing reports no material product revenue.

Changes versus prior comparable periods

• Second-quarter net loss increased to $5.45 million from $5.34 million; first-half net loss increased to $11.14 million from $10.40 million.
• Second-quarter R&D expense fell 13.3% to $2.59 million, while G&A rose 36.9% to $2.60 million. For the first half, R&D fell 14.5% to $5.16 million and G&A rose 48.1% to $5.54 million. Management attributed the G&A increases mainly to stock compensation, professional fees, and directors’ and officers’ insurance.
• First-half operating cash use improved to $7.35 million from $7.92 million.
• Common shares outstanding increased from 40.70 million at year-end 2020 to 86.56 million at June 30, 2021, following substantial equity financings and warrant exercises.
• The company replaced Horizon debt with the SVB facility in June and recorded a $234,419 loss on extinguishment of debt.

Outlook, commentary, risks and unusual items

• Management expected operating losses to continue and stated that available resources, together with potential New Jersey tax-loss sales, were expected to fund operations through the end of 2024. This is an estimate subject to assumptions; the company warned it may need financing sooner or in greater amounts. Additional equity financing could dilute existing holders.
• The Phase III OPTIMA ThermoDox study was stopped after the monitoring committee’s futility recommendation. Following additional analyses, the company discontinued patient follow-up in February 2021; it said retrospective subgroup findings were not a basis to pursue further regulatory discussions.
• GEN-1’s Phase II OVATION 2 study was enrolling. In a February 2021 update, the company reported 34 of approximately 110 patients enrolled and interim R0 resection rates of 80% in the GEN-1 arm versus 58% in the control arm among patients who had surgery. Management then anticipated completing enrollment in the second half of 2021; these are interim, company-reported results, not final efficacy findings.
• The PLACCINE DNA vaccine program was at preliminary research and provisional-patent stage. The filing describes potential platform benefits but reports no clinical efficacy data.
• COVID-19 had not caused significant observed business or operating impacts through the period, according to the company, but could affect financing, trial enrollment, timelines, and future results.
• Two shareholder-related lawsuits concerning ThermoDox statements were ongoing. The company said it intended to defend them; at the early stage, likelihood and range of any loss could not be determined. A separate shareholder action related to the stock incentive plan had been settled in 2020.
• The filing reported no material changes to the risk factors in the 2020 Form 10-K and no off-balance-sheet arrangements or contractual obligations under the stated disclosure.

Important facts for investors to verify

• Whether the stated funding runway through 2024 remains supportable given operating cash use, clinical spending, and the restricted $6 million reserve.
• Current OVATION 2 enrollment, trial status, and whether interim surgical results translate into prespecified clinical endpoints.
• Remaining availability and terms of the SVB facility, including collateral requirements, variable interest, and the end-of-term fee.
• Potential dilution from the large increase in shares outstanding, outstanding equity awards and warrants, and any further capital raises.
• Developments in the ThermoDox-related litigation and any material changes in the status or potential exposure of those cases.